Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) - Total Liabilities
Latest total liabilities as of September 2025: $7.36 Million USD
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has total liabilities worth $7.36 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Drugs Made In America Acquisition Corp. Ordinary Shares - Total Liabilities Trend (2024–2024)
This chart illustrates how Drugs Made In America Acquisition Corp. Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Drugs Made In America Acquisition Corp. Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Drugs Made In America Acquisition Corp. Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HD Renewable Energy Co. Ltd.
TW:6873
|
Taiwan | NT$9.25 Billion |
|
Groupon Inc
NASDAQ:GRPN
|
USA | $667.56 Million |
|
GFT Technologies SE
XETRA:GFT
|
Germany | €374.13 Million |
|
Kamux Oyj
PINK:KMUXF
|
USA | $108.90 Million |
|
Niutech Environment Technology Corp
SHG:688309
|
China | CN¥176.46 Million |
|
Cadiz Inc
NASDAQ:CDZI
|
USA | $100.27 Million |
|
Tanseisha Co., Ltd.
PINK:TAHCF
|
USA | $18.55 Billion |
|
Zhejiang Huilong New Materials Co.Ltd.
SHE:301057
|
China | CN¥812.00 Million |
Liability Composition Analysis (2024–2024)
This chart breaks down Drugs Made In America Acquisition Corp. Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Drugs Made In America Acquisition Corp. Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2024)
The table below shows the annual total liabilities of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $795.67 | -- |